EUVIMEDEUVIMED entdecken
Crossref

Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis

Jefferson A Buendía iD, Diana G Patiño, Erika F Lindarte

Pediatric Pulmonology · 2023-05 · 58 (5) · 1562-1568

DOI: 10.1002/ppul.26361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 27.02.2023. Verfasst von Jefferson A Buendía und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Group in Pharmacology and Toxicology"INFARTO", Department of Pharmacology and Toxicology, University of Antioquia, Medellin, Colombia. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with pulmonary arterial hypertension. This study aims to determine the cost‐utility of ambrisentan regarding sildenafil to treat pediatric patients with pulmonary arterial hypertension in Colombia.

Methods

A decision tree model was used to estimate the cost and quality‐adjusted life‐years (QALYs) of ambrisentan, or sildenafil in pediatric patients with pulmonary arterial hypertension. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost‐effectiveness was evaluated at a willingness‐to‐pay (WTP) value of US$5180.

Results

The base‐case analysis showed that compared with sildenafil, ambrisentan was associated with higher costs and higher QALYs. The expected annual cost per patient with ambrisentan was US$16,105 and with sildenafil was US$1431. The QALYs per person estimated with ambrisentan was 0.40 and for sildenafil was 0.39. The estimated improvement in quality of life and reduced costs results in an estimate of economic dominance for sildenafil over ambrisentan.

Conclusion

Our economic evaluation shows that ambrisentan is not cost‐effective regarding sildenafil to treat pediatric patients with pulmonary arterial hypertension in Colombia. Our study provides evidence that should be used by decision‐makers to improve clinical practice guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryPulmonary Arterial HypertensionHumansChildSildenafil CitrateCost-Benefit AnalysisQuality of LifeFamilial Primary Pulmonary HypertensionPhenylpropionatesPyridazines

Stichwörter der Autor:innen

Colombiacovid-19health economicshealthcarepublic health

Substanzen

Sildenafil CitrateambrisentanPhenylpropionatesPyridazines

Autor:innen und Institutionen

  • Research Group in Pharmacology and Toxicology"INFARTO", Department of Pharmacology and Toxicology, University of Antioquia, Medellin, Colombia.

ORCID-Profile: Jefferson A Buendía

Zitieren

APA

Buendía, J. A., Patiño, D. G., & Lindarte, E. F. (2023). Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis. Pediatric Pulmonology, 58(5), 1562-1568. https://doi.org/10.1002/ppul.26361

Vancouver

Buendía JA, Patiño DG, Lindarte EF. Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis. Pediatric Pulmonology. 2023;58(5):1562-1568. doi:10.1002/ppul.26361

BibTeX
@article{Buenda2023,
  author = {Buendía, Jefferson A and Patiño, Diana G and Lindarte, Erika F},
  title = {Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis},
  journal = {Pediatric Pulmonology},
  year = {2023},
  volume = {58},
  number = {5},
  pages = {1562--1568},
  doi = {10.1002/ppul.26361}
}
Kostenlos starten →